Intuit (NASDAQ:INTU – Get Free Report) had its target price decreased by analysts at KeyCorp from $750.00 to $520.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has an “overweight” rating on the software maker’s stock. KeyCorp’s target price would suggest a potential upside of 27.13% from the […]

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price objective lowered by Wells Fargo & Company from $145.00 to $136.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock. Other research analysts have also recently issued reports about the company. Oppenheimer cut Rhythm Pharmaceuticals from […]

Nutanix (NASDAQ:NTNX – Get Free Report) had its target price decreased by investment analysts at Bank of America from $75.00 to $60.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the technology company’s stock. Bank of America‘s price target indicates a potential upside of 56.09% […]

MercadoLibre (NASDAQ:MELI – Get Free Report) had its price target reduced by Barclays from $2,900.00 to $2,600.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 49.16% from the stock’s previous close. A number of other equities research analysts […]

WillScot (NASDAQ:WSC – Get Free Report) had its target price cut by equities researchers at DA Davidson from $32.00 to $30.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. DA Davidson’s target price suggests a potential upside of 29.27% from the company’s previous close. Other […]

Beta Bionics (NASDAQ:BBNX – Get Free Report) had its target price dropped by equities research analysts at Robert W. Baird from $28.00 to $14.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 0.21% from […]

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by equities research analysts at Wedbush from $110.00 to $88.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 47.08% from […]